Plus Therapeutics
PSTV
4 hedge funds and large institutions have $4.53M invested in Plus Therapeutics in 2016 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
27% less capital invested
Capital invested by funds: $6.25M → $4.53M (-$1.72M)
39% less call options, than puts
Call options by funds: $33K | Put options by funds: $54K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$318K |
| 2 |
PCMI
Princeton Capital Management Inc
Princeton,
New Jersey
|
-$58K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$7K |
| 4 |
JP Morgan Chase
New York
|
-$2K |
| 5 |
KLI
Kelman-Lazarov Inc
Memphis,
Tennessee
|
-$1.59K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
AIM
27
Acrospire Investment Management
Chicago,
Illinois
| – | -$7K | – | – |
|
|
28
JP Morgan Chase
New York
| – | -$2K | – | – |
|
|
KLI
29
Kelman-Lazarov Inc
Memphis,
Tennessee
| – | -$1.59K | – | – |
|
|
PCMI
30
Princeton Capital Management Inc
Princeton,
New Jersey
| – | -$58K | – | – |
|
PSTV Hedge Fund Activity: Q4 2016 in Review
4 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q4 2016, worth a combined $4.53M — down 27% from $6.25M a quarter earlier.
Fund positioning in PSTV was balanced in Q4 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Vanguard Group, cutting an estimated $318K.
- 4 institutional investors held Plus Therapeutics (PSTV) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $4.53M of Plus Therapeutics stock for Q4 2016, down 27% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q4 2016 and 0 closed out.
- The largest Plus Therapeutics seller in Q4 2016 was Vanguard Group, an estimated $318K sold.
Based on aggregated 13F filings for Q4 2016.